# Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients

> **NCT07338344** · PHASE2 · RECRUITING · sponsor: **Rongrong Liu** · enrollment: 78 (estimated)

## Conditions studied

- Transfusion-dependent β-thalassemia Patients

## Interventions

- **DRUG:** Luspatercept combined with low-dose thalidomide
- **DRUG:** Luspatercept plus placebo

## Key facts

- **NCT ID:** NCT07338344
- **Lead sponsor:** Rongrong Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07338344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07338344, "Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07338344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*